Ultra-low-dose Chest CT for HHT

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hereditary Hemorrhagic Telangiectasia Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Telangiectasia, Hereditary Hemorrhagic Telangiectasis Vascular Diseases Vascular Malformations

Age range

1 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ages 1 to 17 years
Diagnosed with positive HHT causing mutations or based on Curacao criteria

Exclusion criteria

Acute respiratory distress
Unstable cardiovascular status
Pneumothorax, hemoptysis
Pulmonary edema
Pulmonary emboli
Fractured ribs or other chest trauma
Recent bronchoscopy
Lung transplantation

Treatment and study plan

Ultra-low dose chest CT

Diagnostic Test

A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.

Primary outcomes

Ultra-low dose images PAVM detection

Time frame: Baseline

Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose)

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2026
First posted: May 5, 2021
Registry last updated: Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed